Bioactive-Enriched Foods Cut Gut Inflammation and Reshape Microbiome in High-Risk Adults

Chronic low-grade inflammation sits at the root of cardiometabolic diseases including obesity, type 2 diabetes, and cardiovascular disease. A disrupted gut microbiota and compromised intestinal barrier allow bacterial lipopolysaccharide (LPS) to leak into the bloodstream—so-called metabolic endotoxemia—amplifying systemic inflammation. Dietary bioactives such as polyphenols, omega-3 fatty acids, soluble fibers, and slowly digestible starch each show individual promise in countering these pathways, but most trials test single ingredients rather than synergistic combinations.

The SINFONI project addressed this gap with a randomized, controlled crossover trial enrolling 30 adults at cardiometabolic risk (50% female, mean age ~44 years, 33% with dyslipidemia but no diabetes or hypertension). Participants consumed either multifunctional (MF) cereal products—enriched with polyphenols, dietary fibers, slowly digestible starch, and PUFAs—or matched control cereal products (without bioactive enrichment) for 8 weeks each, separated by a washout period. Assessments included fasting and postprandial blood and stool biomarkers of intestinal and systemic inflammation, metabolic endotoxemia (LPS, LBP/sCD14), cardiovascular risk markers, gut microbiota composition (16S rRNA sequencing), and serum metabolomics. A one-week fructose supplementation challenge was embedded to probe postprandial metabolic resilience.

The MF intervention produced significant reductions in fecal calprotectin (p = 0.007), a validated biomarker of intestinal mucosal inflammation, and in fasting serum LPS (p < 0.05) compared to control, indicating improved gut barrier integrity and reduced endotoxemia. Serum branched-chain amino acids (BCAAs)—metabolites linked to insulin resistance and microbiome dysbiosis—were also significantly lower following MF consumption. At the microbial level, four taxa increased significantly: Bacteroides ovatus, Bacteroides uniformis, Anaerobutyricum butyriciproducens, and unclassified Christensenellaceae CAG-74, all associated with fiber fermentation, butyrate production, and metabolic health. Despite these intestinal improvements, systemic inflammatory markers and broader cardiometabolic parameters (lipids, glycemia, blood pressure) did not significantly change over the 8-week period.

The findings suggest that a multi-target dietary approach can meaningfully modulate the gut–inflammation axis even in a population without overt disease, and that intestinal endpoints respond before systemic cardiometabolic markers shift—potentially representing an earlier, more sensitive window for dietary intervention. The concurrent rise in fiber-fermenting and short-chain fatty acid–producing bacteria offers a plausible mechanistic link: these bacteria may strengthen the mucosal barrier, reduce LPS translocation, and lower circulating BCAAs through altered amino acid catabolism. The lack of systemic inflammatory change may reflect the relatively short intervention duration, the non-diseased baseline state, or the need for higher doses or longer exposure to propagate gut effects systemically.